Parkinson’s Disease Medications Enter the “Long-Acting Era”: Can Novel Drug Delivery Systems Improve Long-Term Adherence?

In recent years, with the accelerating global aging trend, the number of patients with Parkinson’s disease (PD) has continued to rise. As a typical chronic neurodegenerative disorder, Parkinson’s disease not only causes motor symptoms such as tremors, bradykinesia, muscle rigidity, and balance impairment, but may also be accompanied by non-motor symptoms including sleep disorders, anxiety, depression, and cognitive decline, all of which can significantly affect patients’ quality of life over the long term. Dengyue Pharma has been deeply engaged in the chronic disease field and continues to follow the latest advances in Parkinson’s disease treatment.

Currently, Levodopa remains one of the most essential and classic drugs in Parkinson’s disease therapy. However, with long-term use, traditional levodopa formulations have gradually revealed several limitations, including a short half-life, significant fluctuations in plasma drug concentration, and the need for frequent dosing. As a result, many patients develop motor complications such as the “wearing-off phenomenon,” “on-off phenomenon,” and dyskinesia.

Against this backdrop, global Parkinson’s disease drug development is entering a “long-acting era.” Compared with the past, when the primary focus was simply on drug efficacy, the industry is now placing increasing emphasis on extending drug action duration, stabilizing plasma drug levels, reducing OFF-period fluctuations, and ultimately improving long-term adherence and chronic disease management through novel drug delivery systems.

Why Does Parkinson’s Disease Need Long-Acting Drug Delivery?

Parkinson’s disease is a condition that requires long-term or even lifelong treatment. For most patients, pharmacological therapy not only affects symptom control but also directly impacts daily functioning and overall quality of life. However, traditional levodopa-based therapies have several clear limitations:

Especially in the middle and late stages of the disease, many patients require multiple precisely timed doses each day. Missing or delaying medication, or experiencing abnormal absorption, may rapidly trigger an OFF period, leading to bradykinesia, freezing of gait, or even inability to move independently.

Research suggests that poor long-term adherence may further lead to:

●  Prolonged OFF periods

●  Increased risk of falls

●  Worsening motor fluctuations

●  Higher hospitalization rates

●  Reduced quality of life

Therefore, modern Parkinson’s disease management is no longer focused solely on whether a drug is effective, but increasingly on whether patients can maintain treatment consistently and stably over the long term.

Why Have Long-Acting Formulations Become a Global R&D Focus?

In recent years, “Continuous Dopaminergic Stimulation (CDS)” has gradually become an important therapeutic concept in Parkinson’s disease treatment.

Traditional immediate-release levodopa formulations often cause plasma concentrations to rise rapidly and then fall quickly, creating obvious peak-trough fluctuations. This non-physiological pulsatile stimulation is believed to be closely associated with dyskinesia and motor fluctuations.

The core goal of long-acting drug delivery systems is to provide more stable drug release. Compared with conventional immediate-release formulations, long-acting formulations generally offer the following advantages:

●  Prolonged drug action duration

●  Reduced plasma concentration fluctuations

●  Shortened OFF periods

●  Reduced dosing frequency

●  Improved long-term adherence

●  Better quality of life

As a result, many pharmaceutical companies worldwide are actively developing long-acting delivery systems for Parkinson’s disease therapies.

Extended-Release Capsules: Prolonging the Action of Levodopa

Extended-release capsules are among the earliest important strategies in the long-acting development of Parkinson’s disease drugs.

One representative product is Rytary (IPX066), approved by the FDA. Unlike conventional levodopa formulations, it utilizes a combination of:

●  Immediate-release granules

●  Extended-release beads

●  Enteric-coated delivery systems

This design enables patients to rapidly enter the ON phase while maintaining stable drug release for a longer period.

For patients in the middle and advanced stages of Parkinson’s disease, stable drug release is especially important.

Osmotic Pump Technology Is Enhancing Precision-Controlled Release

In addition to extended-release capsules, osmotic pump tablets have become another important development direction in recent years.

Traditional oral tablets release drugs relatively quickly, often leading to fluctuations in therapeutic effects. Osmotic pump systems, however, can achieve more stable drug release through specially designed controlled-release structures.

Their core mechanisms include:

●  Osmotic pressure-driven drug release

●  Controlled drug release rates

●  Extended drug maintenance duration

●  Stabilized plasma drug concentrations

Compared with conventional tablets, osmotic pump technology offers advantages such as more precise controlled release, smaller peak-trough fluctuations, and fewer motor fluctuations. This development also suggests that Parkinson’s disease treatment is gradually evolving from “standard sustained release” into the era of “precision-controlled release.”

Inhalation Formulations: Rapid Relief for OFF Periods

Traditional oral levodopa formulations have a relatively slow onset of action, while some patients experience sudden OFF episodes. Therefore, rapid-onset delivery systems have become another important focus.

One notable innovation is Inbrija, a levodopa inhalation powder.

Its core concept is simple: bypass the gastrointestinal tract through pulmonary absorption.

Compared with oral medications, its main characteristics include:

●  Faster onset of action

●  Less affected by gastric emptying

●  Rapid relief of OFF periods

●  Self-administration by patients

●  Better suitability for acute motor fluctuations

Studies have shown that some patients experience significant improvement in motor symptoms within 30 minutes after inhalation.

This model also indicates that Parkinson’s disease treatment is gradually shifting from solely “long-term maintenance therapy” toward an integrated approach combining “maintenance therapy + rapid rescue treatment.”

Long-Acting Microspheres and Transdermal Patches Are Reducing Dosing Frequency

In recent years, long-acting dopamine receptor agonists have also become a major research focus. These include:

●  Long-acting microspheres

●  Transdermal patches

●  Long-acting injectable formulations

●  In situ gels

Rotigotine is one of the most important representatives in this field. Currently, rotigotine transdermal patches are widely used for Parkinson’s disease treatment.

Compared with oral medications, transdermal administration can provide continuous and stable drug release while avoiding gastrointestinal interference. However, daily patch application may still be inconvenient for some patients.

As a result, long-acting microsphere technology has continued to advance. Novel long-acting rotigotine microspheres can achieve:

●  Once-weekly injection

●  Sustained long-acting release

●  More stable plasma concentrations

●  Fewer dosing occasions

For patients with swallowing difficulties, memory impairment, or those requiring long-term polypharmacy, long-acting formulations may significantly improve treatment adherence.

Conclusion

Parkinson’s disease medications are entering the “long-acting era.”

From extended-release capsules and osmotic pump tablets to inhalation powders, intestinal infusion systems, and long-acting microspheres, novel drug delivery systems are continuously improving the long-term treatment experience for Parkinson’s disease patients.

Compared with traditional frequent dosing regimens, long-acting drug delivery systems may not only stabilize plasma drug concentrations and reduce OFF-period fluctuations, but also further improve long-term adherence and quality of life.

In the future, with the continued advancement of precision-controlled release, long-acting delivery technologies, and intelligent chronic disease management systems, Parkinson’s disease treatment may truly evolve from simple “symptom control” toward a new era of “long-term precision management.”